September 29, 2025.
FAMAR Group is pleased to announce the appointment of Dr. Riku Rautsola as CEO, effective September 29, 2025. Riku has served as a non-executive member of FAMAR’s Board of Directors and an advisor to MidEuropa during the acquisition of FAMAR last year. Riku has an extensive global executive career spanning more than 30 years in the pharmaceutical, biotech and CDMO industries, having held CEO and senior executive positions at several leading companies, creating sustained profitable growth.
Born in Tampere, Finland, Riku Rautsola holds a PhD in Health Economics from Ludwig-Maximilians-University of Munich, Germany. He is a holder of several applicational patents and awards for his internationally recognised achievements.
Under Riku’s leadership, FAMAR remains committed to serve its global customers, expand production capacity, accelerate its development partnerships, and invest in its people. Riku will also continue to serve as a member of the Board of Directors.